Abstract
Background Human genetics is an important tool for identifying genes as potential drug targets, and the extensive genetic study of cardiovascular disease provides an opportunity to leverage genetics to match specific patient populations to specific drug targets to improve prioritization of patient selection for clinical studies.
Methods We selected well described genetic variants in the region of PCSK9 (rs11591147 and rs562556), ADRB1 (rs7076938), ACE (rs4968782 and rs4363) and BAG3 (rs2234962) for use as proxies for the effects of drugs. Time-to-event analyses were utilized to evaluate their effects on atrial fibrillation (AF) and heart failure (HF) death and/or re-hospitalization using real-world longitudinal dataset. To mitigate the effect of confounding factors for cardiovascular (CV) outcomes, we employed propensity score matching.
Results After matching, a genetic proxy for PCSK9 inhibition (rs11591147) improved survival from CV death/heart transplant in individuals following a diagnosis of ischemic heart disease (Hazard Ratio (HR) 0.78, P=0.04). A genetic proxy for beta-blockade (rs7076938) improved freedom from rehospitalization or death in individuals with AF (HR 0.92, P=0.001), and a genetic proxy of ACE inhibition (rs7076938) improved freedom from death or rehospitalization for HF (HR 0.84, P=0.017) and AF (HR 0.85, P=0.0014). A protective variant in BAG3 (rs2234962) showed decreased risk of HF rehospitalization or CV death/heart transplant composite outcome within 10 years in HF patients (HR=0.96, P=0.033). Notably, despite smaller cohort sizes after matching, we often observed numerically smaller HRs and reduced P, indicating more pronounced effects and increased statistical association. However, not all genetic proxies replicated known treatment effects.
Conclusions Genetic proxies for well-known drugs corroborate findings from clinical trials in cardiovascular disease. Our results may demonstrate a novel analytical approach that leverages genetic evidence from a large cohort to effectively select patient populations where specific drug targets may be most effective.
Competing Interest Statement
All authors are employees or contractors of Tenaya Therapeutics a publicly traded biopharmaceutical company exclusively focused on Cardiovascular Disease. FF, WY, TH, WW JRP, SMF are shareholders of Tenaya Therapeutics
Funding Statement
This study was performed by employees and contractors of Tenaya Therapeutics
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Genetic and clinical data in the UKB cohort were obtained from the UKB (https://www.ukbiobank.ac.uk) and is available to researchers through a streamlined application process. The UK Biobank was approved by the North West Multi-Centre Research Ethics Committee and all participants provided written informed consent to participate in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Genetic and clinical data in the UKB cohort were obtained from the UKB (https://www.ukbiobank.ac.uk) and are available to any qualified researcher worldwide through a streamlined application process.
